LaurenElizabethDockeryMD

Obstetrics & Gynecology • Oklahoma City, OK

Gynecologic Oncology

Physician

Join to view full profile

Dr. Dockery is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dockery's full profile

Already have an account?

Office
800 NE 10th St
Ste 5050
Oklahoma City, OK 73104
Phone+1 405-271-8001

Fax+1 919-966-2646

Education & Training

Tufts Medical CenterResidency, Obstetrics and Gynecology, 2012 - 2016
Virginia Commonwealth University School of MedicineClass of 2012

Certifications & Licensure

OK State Medical License 2015 - 2025
NC State Medical License 2019 - 2023
MA State Medical License 2012 - 2016
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Start of enrollment: 2020 Jun 29
Completed
Phase 1
Roles: Contact

Publications & Presentations

PubMed

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le
Journal for Immunotherapy of Cancer. 2025-01-11
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Debra L Richardson, Julia C F Quintanilha, Natalie Danziger, Gerald Li, Ethan Sokol
Clinical Cancer Research. 2024-10-15
1 citations
Developing a Novel Image Marker to Predict the Clinical Outcome of Neoadjuvant Chemotherapy (NACT) for Ovarian Cancer Patients.
Ke Zhang, Neman Abdoli, Patrik Gilley, Youkabed Sadri, Xuxin Chen
Arxiv. 2024-07-03

Press Mentions

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with Nab-Sirolimus at Society of Gynecologic Oncology (SGO)March 18th, 2024